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ABSTRACT
Prostate cancer is the most common non-skin ma-
lignancy in men. Almost all men who die from pros-
tate cancer have hormone-refractory prostate cancer
with metastasis to bone. Emerging supportive treat-
ments—including chemotherapy, bisphosphonates,
and surgery—require integration that is optimized
in a multidisciplinary setting. A multidisciplinary
clinic for bone metastases has been in place at Tor-
onto–Sunnybrook Regional Cancer Centre since
1999, combining orthopedic surgery, radiation on-
cology, interventional radiology, and palliative medi-
cine for all patients with bone metastases. The
addition of a prostate-focused multidisciplinary clinic
integrates these services for patients with advanced
prostate cancer.
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1. INTRODUCTION
Prostate cancer is the fourth most common cancer
worldwide and the most common cancer in Canada
among men 1,2. An estimated 20,500 new cases of
prostate cancer (PCA) occurred in 2005 in Canada,
and an estimated 4300 men will die as a result 1. In
Ontario alone, PCA was found to be the most frequently
diagnosed cancer, with an estimated 8300 new cases
in 2005 1. Most patients with advanced disease will
develop metastases. The most common metastatic site
is bone, with bone metastases being found in approxi-
mately 80% of advanced PCA patients 3.
Over recent decades, patient survival times have
increased because of improved radiotherapy and sys-
temic treatments 4,5. Analgesic therapy and radiation
therapy to bone have been the cornerstone of pallia-
tion in patients with hormone-refractory PCA meta-
static to bone. The recent addition of taxane-based
chemotherapy and bisphosphonates is helpful, but
many patients may not be accessing these valuable
therapies in a timely manner. The establishment of a
prostate bone metastasis clinic in a tertiary care cen-
tre will provide timely multidisciplinary care to pa-
tients with advanced PCA.
2. DISCUSSION
2.1 Metastatic Occurrence in Bone
Cancer metastasis to bone can occur in hormone-
sensitive disease, but it may also develop or progress
during the hormone-refractory stage. In prostate can-
cer, metastases tend to be more osteoblastic than
osteolytic: cancer cells produce factors that stimu-
late osteoblast proliferation, causing increased abnor-
mal bone formation rather than bone breakdown 6.
Although androgen deprivation therapy is highly ef-
fective in treating hormone-sensitive PCA, almost all
patients become resistant after a median of 18–
24 months. In the setting of castrate serum testoster-
one levels, resistance is often indicated by a rising
level of prostate-specific antigen (PSA) before symp-
toms progress. With continuing improvement in sys-
temic therapies such as chemotherapy, the overall
survival of patients with hormone-refractory PCA is
increasing 3. However, recent studies have shown
that androgen deprivation therapy has harmful ef-
fects on the skeleton. The accelerated bone loss po-
tentially puts men at higher risk of skeletal
complications 3.
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2.2 Complications
Bone metastases are not life-threatening in themselves,
but their presence generally indicates a poor progno-
sis 7. In PCA patients, the most common skeletal sites of
metastases are the pelvic bones, vertebral column, ribs,
and long bones, particularly the femur and humerus 7,8.
Predictors of skeletal morbidity include extensive bone
lesions seen on diagnostic imaging, poor performance
status, severe bone pain, and an increase in PSA level 8.
Morbidity stems from the various complications
from bone metastases. Skeletal-related events (SREs)
include debilitating bone pain in up to 80% of pa-
tients with bone metastases, impaired mobility in
65%–75%, vertebral collapse or deformity in 18%,
hypercalcemia in 10%–15%, spinal cord compres-
sion in 12% of PCA patients, and pathologic fracture
in 9% 9–12. These complications may cause deformity,
postural problems, and loss of motor and sensory
function (neurologic impairment), leading to de-
creased overall quality of life (QOL) 13. Management
of bone metastases has changed from solely provid-
ing pain relief to improving QOL and survival 14.
2.3 Available Treatments
Current treatment options for PCA patients with bone
metastases include external beam radiotherapy, surgery,
systemic therapy (bisphosphonates, hormonal therapy,
and chemotherapy), and management with pain medi-
cations 5,15. The goals of these therapies are to reduce
the incidence of SREs, reduce bone pain and morbidity,
and improve the patient’s mobility and overall QOL 2,5.
Patients with metastatic disease are treated with pallia-
tive intent. Each of the available treatments depends
on the patient’s underlying health and performance sta-
tus, the location of the metastases, the treating physi-
cian, and the facilities available in the local area 15.
Analgesic therapy and radiation remains the treat-
ment of choice for localized metastasis-related bone
pain 12. Radiation is also effective in preventing im-
pending fractures, reducing bone pain, and promot-
ing healing in pathologic fractures 16. About 80%–90%
of patients treated with radiotherapy for bone me-
tastases experienced pain alleviation 16. Unfortunately,
some of these patients eventually experience a recur-
rence in pain at the previously radiated skeletal site 5.
Patients with painful lesions larger than 2.5 cm
in diameter and with more than 50% of cortical bone
destroyed in a weight-bearing bone are at high risk
of experiencing a pathologic fracture and may need
surgical intervention 7. Internal fixation or prophy-
lactic orthopedic fixation will allow for better QOL
through pain relief, stability maintenance, mobility,
and recovery of weight-bearing capacity 14,16,17. Sur-
gery is usually reserved for patients with good per-
formance status and a life expectancy of at least
6 months so that sufficient time and strength are
available for recovery and rehabilitation 12,18,19.
General anesthesia in surgical intervention is not
without risk, especially for patients in advanced stages
of cancer 14. For those with vertebral metastasis, an
alternative surgical approach is vertebroplasty, which
uses injections of polymethylmethacrylate bone ce-
ment into the vertebral body to restore spinal stability
and relieve pain 14.
The advantage of systemic therapy is the ability
to deliver the treatment throughout the body 20. Two
large randomized studies established that docetaxel-
based chemotherapy can improve median survival
in patients with metastatic hormone-refractory
PCA 21,22. In addition, taxane-based chemotherapy is
more effective in palliating symptoms of metastatic
PCA than are mitoxantrone and prednisone 23. Also,
bisphosphonates can help treat bone metastases in
PCA patients by inhibiting osteoclastic activity. How-
ever, several randomized studies of clodronate and
pamidronate failed to demonstrate significant ben-
efit in terms of pain relief 5,24,25. A randomized pla-
cebo-controlled study conducted by Saad et al. 26,27
with a third-generation bisphosphonate—zoledronic
acid—demonstrated a reduction in the number of
SREs and extension of the time to first SRE by approxi-
mately 150 days. Based on that study, zoledronic acid
has been approved by Health Canada and the U.S.
Food and Drug Administration for the treatment of
hormone-refractory PCA.
Analgesic therapy requires a comprehensive pain
assessment and an understanding of the causes of pain
and of pain management. Opioids may then be ap-
propriately initiated, titrated, and augmented with
adjuvants including steroids, nonsteroidal anti-
inflammatory agents, and a variety of other agents
that specifically target the neuropathic pain commonly
seen in the setting of bone metastases 28.
2.4 Poor Integration of Services
The variety of PCA treatments has unfortunately trans-
lated into a lack of coordination between the special-
ists responsible for treating the patient. Treating bone
pain caused by metastatic disease is a multifaceted
task. At the moment, many patients wait for separate
appointments to see each specialist (for example, the
radiation oncologist, medical oncologist, orthopedic
surgeon, and palliative medicine physician), often in
sequence, which compounds wait times. Timing is
key to the effective treatment of patients with im-
pending pathologic fracture, spinal cord compression,
and bone pain. Early diagnosis and treatment are vital
for the patient’s QOL and for the prevention of perma-
nent or further neurologic damage 9,12.
2.5 New Multidisciplinary Prostate Bone Metastases
Clinic
The current Bone Metastases Clinic (BMC) at Toronto–
Sunnybrook Regional Cancer Centre has been operatingMULTIDISCIPLINARY PROSTATE BONE METASTASES CLINIC
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since 1999. The BMC offers a multidisciplinary ap-
proach to the care of cancer patients with symptom-
atic bone metastases in a tertiary cancer center. The
new multidisciplinary Prostate Bone Metastases Clinic
(PBMC) will overlap with the BMC to help provide pa-
tients with the best possible care for their cancer.
The PBMC will be a one-stop clinic at which pa-
tients will have the opportunity to see a variety of
doctors, based on need. The team of specialists will
focus on providing the best therapeutic options and
combinations, tailored specifically to the individual.
The clinic will greatly facilitate direct communica-
tion between the health care specialists. Community
urologists usually manage the care and make the re-
ferrals for PCA patients receiving hormonal therapy.
Therefore, PBMC will address the need for a simpli-
fied referral to an all-in-one clinic for patients requir-
ing more than one specialist.
The PBMC will have a team of 5 radiation on-
cologists, 1 medical oncologist, 1 interventional ra-
diologist, 3 orthopedic surgeons, 2 palliative medicine
physicians, a radiation therapist, a primary nurse co-
ordinator, and a research assistant. Each patient will
have the opportunity to receive specialized care in-
cluding radiation therapy, systemic therapy (chemo-
therapy, bisphosphonates, and hormonal therapy),
pain management, surgical intervention, and support-
ive care where applicable. The patient will also ben-
efit from the savings in time, money, and energy that
would otherwise be spent on travel and waits for
separate specialist appointments.
The new multidisciplinary PBMC will be held every
Monday afternoon in conjunction with the regular
BMC occurring on the second and fourth Friday of
each month. Thereafter, the patients will be followed
up at the medical oncologist’s regular clinic. The PBMC
will provide optimal service for PCA patients through
its multidisciplinary approach. In addition, the venue
will facilitate clinical research, such as novel bone-
targeted therapies, chemotherapies, and improve-
ments in radiation therapy, thereby augmenting the
clinic’s ability to effectively treat patients with the
latest research and evidence-based care.
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